Alterations have been demonstrated in ligand and cognate receptor system of the transforming growth factor beta (TGF-b) pathway in prostate cancer (PC). Still, little is known about changes in the activity of the intracellular Smad cascade of TGF-b signaling during prostate carcinogenesis. We used immunohistochemistry to analyze phosphorylated Smad2 (p-Smad2), nuclear Smad4 and inhibitorySmad7 in epithelial cells of normal, hyperplastic and malignant prostate. Specimens comprised 49 tissue cores of PC, 10 benign prostate hypertrophies and three normal prostates. Nuclear p-Smad2 (Po0.001) and nuclear Smad4 (P ¼ 0.023) were significantly decreased in PC with remarkable variations in cytoplasmic Smad7 levels. Substantial decreases in p-Smad2 and Smad4 levels were found in specimens with primary Gleason grades 3 and 4, whereas in grade 5, levels were markedly higher. Our results provide the first evidence for changes and reversible attenuation in the Smad system of the TGF-b pathway during prostate carcinogenesis.
Introduction
Prostate cancer (PC) is the most common form of cancer and a major cause of cancer deaths among men in the Western world. 1 When the tumor is localized to the prostate, the relative cure rate by either radical prostatectomy or radiation therapy is high. However, if the cancer is detected at an advanced stage, when the disease has already spread outside the prostate, the prognosis for survival is dramatically decreased. The precise molecular mechanisms involved in prostate carcinogenesis remain uncertain, but obviously disruption in the balance of proliferation and apoptosis of epithelial cells is a key event. In this regard, a number of studies have focused on alterations in transforming growth factor-beta (TGF-b) signaling during prostate carcinogenesis. 2, 3 Transforming growth factor-beta expressed as three isoforms is known to inhibit the growth and induce apoptosis of normal prostate (NP) cells. 4 In early tumorigenesis, it functions as a tumor suppressor, 2, 3, 5 whereas in later stages of tumor progression, it acts as a tumor promoter. 3, 5 The variety of TGF-b responses in malignant cells apparently involve well-documented changes in TGF-b expression 2 and loss of TGF-b receptors (TbRs) during carcinogenesis. 6, 7 However, much less is known about possible changes in intracellular pathway mediators of TGF-b signaling during the progression of PC. 3 Cellular responses of all TGF-b family members including activins and bone morphogenetic proteins arise by binding to and activating specific cell surface receptors. 8, 9 The basic route for the intracellular events of signaling is mediated by the family of Smad proteins comprising eight members (Smad 1-8) divided into three subcategories with distinct functions. 8 Of these, Smad2 and Smad3 mediate TGF-b and activin signaling pathways, being activated via phosphorylation of their cognate receptors. 10 Receptor-activated Smad2 and Smad3 subsequently form heteromeric complexes with the common mediator Smad4 and then translocate to the nucleus, where they act as ligand-induced transcription regulators of target genes. 8, 9 Among upregulated target genes is Smad7. This inhibitory Smad has been shown to antagonize activation of Smad2 and Smad3, thereby creating a negative feedback loop. 8 Studies on TGF-b/ activin signaling in PC cell lines have demonstrated the crucial roles of Smads in mediating TGF-b/activin signaling as well as crosstalk with androgen and mitogen-activated protein kinase pathways. 8, 10, 11 In addition, the role of Smad2 and Smad3 in prostate biology has been studied in LNCaP cell line by withdrawing Smad3. 12 The results suggest that Smad3 is not required for activin-mediated growth inhibition effects in PC cells. However, evidence of changes in these mediators in pathologic changes of prostate is limited, except for the reports of alterations in the Dunning prostatic carcinoma model and Smad4 expression during the progression of PC. [13] [14] [15] In this study, we compared TGF-b/activin signaling activity, performing immunohistochemical analysis of the levels of activated Smad2, nuclear Smad4 and Smad7 in NP, benign prostate hypertrophy (BPH) and PC specimens.
Materials and methods

Tissue specimens
Human prostate tissue array containing 49 tissue cores of cancer and two BPHs was obtained from InnoGenex (San Ramon, CA, USA). Formalin-fixed and paraffin-embedded tissue specimens of three NPs adjacent to urinary bladder carcinoma and 10 BPHs were obtained from patients undergoing cystoprostatectomy or TURP at Tampere University Hospital (TLJT). Sections of NPs and BPHs were cut at 5 mm. A section of each specimen including tissue array was stained with hemotoxylin and eosin to verify histopathological diagnosis and Gleason grading (PMM). This project was approved by the Ethical Committee of the Tampere University Hospital.
Immunohistochemistry
Polyclonal phosphorylated Smad2 Ser465/467 (p-Smad2) antibody was obtained from Cell Signaling Technology (Beverly, MA, USA). This antibody is produced by immunizing rabbits with a synthetic phospho-peptide (KLH-coupled) corresponding to residues around Ser465/467 of human Smad2 and purified by protein A and peptide affinity chromatography. Smad4 and Smad7 proteins were detected using antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Of these, B-8 is a mouse monoclonal IgG1 antibody raised against a recombinant protein corresponding to amino acids 1-552, representing full-length Smad4 of human origin, whereas H-79 is a rabbit polyclonal antibody raised against a recombinant protein corresponding to amino acids 319-397 mapping near the carboxy-terminus of Smad7 of human origin. Specimens fixed in neutralbuffered formalin were deparaffinized in xylene and rehydrated. Endogenous peroxidase activity was suppressed with 0.5% hydrogen peroxide in methanol before unmasking in sodium citrate target retrieval solution, pH 6.0. After preincubation with saturation solution (Histostain s -Plus kit; Zymed Laboratories, South San Francisco, CA, USA) to block nonspecific sites, the sections were incubated with anti-p-Smad2 1:100, anti-Smad4 1:100 or anti-Smad7 1:300 in a humidified chamber overnight at þ 41C. Antigenic binding sites were visualized with a serial incubation with biotinylated secondary antibody, followed by streptavidin-biotin peroxidase complex and diaminobenzidine tetrahydrochloride (Histostain s -Plus kit; Zymed Laboratories) before counterstaining with Mayer's hematoxylin. Negative control sections of NPs and BPHs were processed in an identical manner by substitution of primary antibody with normal rabbit IgG for anti-Smad4 and anti-Smad7 and with normal mouse IgG for p-Smad2.
Assessment of immunohistochemistry
Immunostaining of epithelial cells was assessed by two independent investigators (MCP and HS). Both cytoplasmic and nuclear immunostaining were observed for Smad4 and Smad7, whereas immunostaining for pSmad2 was localized almost exclusively to the nuclear compartment. To study the activity of TGF-b/activin signaling pathway, levels of p-Smad2 and Smad4 were analyzed by means of nuclear immunoreactivity (NIR), whereas in the case of Smad7, cytoplasmic immunoreaction was estimated. To analyze nuclear p-Smad2 and Smad4 levels, NIR was first counted at a magnification of Â 1000 for both proteins in normal specimens (n ¼ 3) and reported as a percentage of the total number of cells counted. At least seven randomly selected areas were counted from each normal specimen (n ¼ 3). The average NIR of secretory and basal epithelial cells for p-Smad2 was 9970.89% and 9870.98% for nuclear Smad4. Then, expression categories for NIR were created: negative expression (NIRo5%), low expression (NIRo50%), reduced expression (NIRo95%) or preserved expression (NIRX95%). The remaining specimens were categorized by visual estimation at a magnification of Â 400, covering all areas of tissue cores. In borderline cases or with conflicting results by the two investigators, specimens were counted as described above. Cytoplasmic immunoreactivity for Smad7 was analyzed at a magnification of Â 400 and assessed on an intensity scale as negative; 0, weak; 1, moderate; 2, strong; 3. In cases of disagreement, the samples were reviewed and consensus reached. Detached or otherwise damaged tissue sections were excluded from the analysis, which resulted in unequal number of cases between analyses.
Statistical analysis
Results are reported as mean7s.d. Fisher's exact test was applied to determine statistical significance. Kappa coefficient (k) was used to measure agreement between p-Smad2 and Smad4.
Results
Comparison of p-Smad2, nuclear Smad4 and cytoplasmic Smad7 levels in epithelial cells of normal, benign prostate hypertrophy and malignant prostate tissue Immunoreactivity of p-Smad2 was localized almost exclusively to the nuclei of prostatic cells, the finding corresponding to the known activation pathway of Smad2 (Figure 1 ). The analysis of NIR in normal specimens revealed that almost all epithelial cells exhibit active Smad2 (9970.89% positively stained). The epithelium of BPH demonstrated preserved levels (NIRX95%) of nuclear p-Smad2-positive cells (Table 1 ) and only one specimen showed a reduced (NIR o95%) level. Of the 35 Smad2 and Smad4 in human prostate cancer MC Perttu et al PC specimens, 27 exhibited low (NIR o50%) or reduced levels but no negative cases were found. Smad4 expression was localized both in the cytoplasmic and nuclear compartments of prostatic epithelial cells (Figures 1 and   2 ). Normal prostate specimens showed high NIR in epithelial cells (9870.98% positively stained). Also, nearly all (5/6) BPH specimens demonstrated preserved levels of nuclear Smad4, whereas in PC, only 17/40 of specimens showed preserved nuclear expression (Table 1) . In 4/40 of PC cases, NIRo5% was observed and considered negative. Taken together, a significant decrease in the levels of nuclear immunopositive epithelial cells for p-Smad2 (1/10 vs 27/35; Po0.001) and Smad4 (1/9 vs 23/40; P ¼ 0.023) was observed when benign (NP þ BPH) specimens were compared to PC specimens. In addition, there was a good level of agreement (k40.6) of NIRs of p-Smad2 to Smad4 in the same PC specimens.
Immunostaining of Smad7 in our analysis was localized both in the cytoplasmic and nuclear compartments of epithelial cells. As activation of TbR has been shown to induce cytoplasmic localization of Smad7, we analyzed levels of Smad7 in this cellular compartment. 16 In all NP and BPH cases, cytoplasmic immunostaining of Smad7 was scored low or moderate. Moreover, majority (28/44) of PC cases demonstrated low or moderate levels but 14% (6/44) of cases appeared totally negative and 23% (10/44) revealed stronger cytoplasmic immunostaining than the benign specimens (Table 1) .
To study the activity of TGF-b signaling in different stages of tumorigenesis, we compared immunoanalysis of Smads to primary Gleason grade of tissue specimens. We found that with an increase in grade from Gleason 3 to Gleason 4, PCs demonstrated a progressive loss of nuclear p-Smad2 and Smad4 immunoreactivity (Table 2) . Nevertheless, PCs representing Gleason grade 5 demonstrated mainly preserved nuclear p-Smad2 and Smad4 levels, close to those observed in benign tissue samples. No similar change in levels of cytoplasmic Smad7 with different Gleason grades was detected ( Table 2 ).
Discussion
Our finding indicates that p-Smad2 levels are signicantly decreased in PC. As no evidence for mutation or 
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Negative Low Moderate Strong Difference vs benign Smad2 and Smad4 in human prostate cancer MC Perttu et al abnormal mRNA expression of Smad2 gene in human PC has been found, 17 disruption(s) in the Smad2 activation process is most likely involved. This may include the reported loss of TbRs during prostate carcinogenesis 6, 7 or a possible overexpression of inhibitory Smad7. 18 Based on the current view of the Smad activation pathway, after being phosphorylated by TbRI, Smad2 forms heteromeric complexes with Smad4 and these activated complexes then accumulate in the nucleus. 8 It could be assumed that the decrease in nuclear Smad4 may be a consequence of the lack of activated complex formation partners like p-Smad2. In this respect, a similar decrease in nuclear Smad4 and loss of Smad8 in PC progression has been recently reported by Horvath et al.
14 Although previous studies have indicated that expression of Smad4 is decreased or even lost in many cancers, 19, 20 mutational inactivation of Smad4 in PC is suggested to be an uncommon event. 20 Also, in this study, only two cases were found with totally undetectable immunostaining of Smad4.
Overexpression of inhibitory Smad7 could be one explanation for decreased nuclear p-Smad2 levels. Here, Smad2 and Smad4 in human prostate cancer MC Perttu et al it should be noted that regulation of Smad7 expression is not restricted to TGF-b family members, as epidermal growth factor, tumor necrosis factor-a and interferon-g have been shown to independently regulate the expression of Smad7. 8 Although cytoplasmic Smad7 levels in PC differed from those seen in benign specimens, the difference was not statistically significant. This led us to the conclusion that changes in Smad7 activity alone most likely do not explain decreased levels of p-Smad2 in PC. The finding that in a subset of PCs, expression of the Smad7 gene might be abrogated is interesting in the light of the suggested role of Smad7 as a mediator of TGF-binduced apoptosis in prostatic carcinoma cells. 18 The changes observed in p-Smad2 and Smad4 provide evidence for the view that during prostate carcinogenesis, Smad-mediated TGF-b/activin signaling is first reduced owing to the loss of receptor expression. At the very late phases of carcinogenesis, activity of the signaling system recovers by a mechanism yet to be characterized. 9 Kang et al. 21 recently reported a switch of the Smad pathway from tumor suppressor to prometastatic in the development of breast cancer bone metastasis, but further studies are needed to determine if similar changes occur during prostate carcinogenesis.
Conclusions
This study provides evidence for altered signaling through Smad proteins (Smad2 and Smad4) in human PC. The changes in levels of signaling components may reflect the suggested dualistic role of TGF-b in cancer progression. 5 The results warrant further studies to clarify the activity of Smads, as well as the functional role of individual Smads at different stages of prostate carcinogenesis.
